Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 138

Similar articles for PubMed (Select 21708300)

1.

The type II collagen N-propeptide, PIIBNP, inhibits cell survival and bone resorption of osteoclasts via integrin-mediated signaling.

Hayashi S, Wang Z, Bryan J, Kobayashi C, Faccio R, Sandell LJ.

Bone. 2011 Oct;49(4):644-52. doi: 10.1016/j.bone.2011.06.011. Epub 2011 Jun 25.

2.

Type IIB procollagen NH(2)-propeptide induces death of tumor cells via interaction with integrins alpha(V)beta(3) and alpha(V)beta(5).

Wang Z, Bryan J, Franz C, Havlioglu N, Sandell LJ.

J Biol Chem. 2010 Jul 2;285(27):20806-17. doi: 10.1074/jbc.M110.118521. Epub 2010 May 3.

3.

Integrin-mediated signaling in the regulation of osteoclast adhesion and activation.

Duong LT, Rodan GA.

Front Biosci. 1998 Aug 1;3:d757-68. Review.

4.

Unoccupied alpha(v)beta3 integrin regulates osteoclast apoptosis by transmitting a positive death signal.

Zhao H, Ross FP, Teitelbaum SL.

Mol Endocrinol. 2005 Mar;19(3):771-80. Epub 2004 Dec 9.

PMID:
15591537
5.

The matricellular protein CYR61 inhibits osteoclastogenesis by a mechanism independent of alphavbeta3 and alphavbeta5.

Crockett JC, Schütze N, Tosh D, Jatzke S, Duthie A, Jakob F, Rogers MJ.

Endocrinology. 2007 Dec;148(12):5761-8. Epub 2007 Sep 6.

PMID:
17823253
6.

Beta 1 integrins and osteoclast function: involvement in collagen recognition and bone resorption.

Helfrich MH, Nesbitt SA, Lakkakorpi PT, Barnes MJ, Bodary SC, Shankar G, Mason WT, Mendrick DL, Väänänen HK, Horton MA.

Bone. 1996 Oct;19(4):317-28.

PMID:
8894137
7.

Involvement of alpha(v)beta3 integrins in osteoclast function.

Nakamura I, Duong le T, Rodan SB, Rodan GA.

J Bone Miner Metab. 2007;25(6):337-44. Epub 2007 Oct 25. Review.

PMID:
17968485
8.
9.

Peptidomimetic antagonists of alphavbeta3 inhibit bone resorption by inhibiting osteoclast bone resorptive activity, not osteoclast adhesion to bone.

Carron CP, Meyer DM, Engleman VW, Rico JG, Ruminski PG, Ornberg RL, Westlin WF, Nickols GA.

J Endocrinol. 2000 Jun;165(3):587-98.

10.

Contortrostatin, a homodimeric snake venom disintegrin, is a potent inhibitor of osteoclast attachment.

Mercer B, Markland F, Minkin C.

J Bone Miner Res. 1998 Mar;13(3):409-14.

PMID:
9525341
11.

Integrin function in osteoclasts.

Rodan SB, Rodan GA.

J Endocrinol. 1997 Sep;154 Suppl:S47-56. Review.

12.
13.

Regulatory mechanism of osteoclast activation.

Nakamura I, Rodan GA, Duong le T.

J Electron Microsc (Tokyo). 2003;52(6):527-33. Review.

PMID:
14756240
14.

Role of alpha(v)beta(3) integrin in osteoclast migration and formation of the sealing zone.

Nakamura I, Pilkington MF, Lakkakorpi PT, Lipfert L, Sims SM, Dixon SJ, Rodan GA, Duong LT.

J Cell Sci. 1999 Nov;112 ( Pt 22):3985-93.

15.

Localization and possible role of two different alpha v beta 3 integrin conformations in resting and resorbing osteoclasts.

Faccio R, Grano M, Colucci S, Villa A, Giannelli G, Quaranta V, Zallone A.

J Cell Sci. 2002 Jul 15;115(Pt 14):2919-29.

16.

Abnormal localisation and hyperclustering of (alpha)(V)(beta)(3) integrins and associated proteins in Src-deficient or tyrphostin A9-treated osteoclasts.

Lakkakorpi PT, Nakamura I, Young M, Lipfert L, Rodan GA, Duong LT.

J Cell Sci. 2001 Jan;114(Pt 1):149-160.

17.
18.

Fibronectin inhibits osteoclastogenesis while enhancing osteoclast activity via nitric oxide and interleukin-1β-mediated signaling pathways.

Gramoun A, Azizi N, Sodek J, Heersche JN, Nakchbandi I, Manolson MF.

J Cell Biochem. 2010 Nov 1;111(4):1020-34. doi: 10.1002/jcb.22791.

PMID:
20672308
19.

Diversity of bone matrix adhesion proteins modulates osteoblast attachment and organization of actin cytoskeleton.

Demais V, Audrain C, Mabilleau G, Chappard D, Baslé MF.

Morphologie. 2014 Jun;98(321):53-64. doi: 10.1016/j.morpho.2014.02.003. Epub 2014 Apr 13.

PMID:
24735942
20.

Design and characterization of orally active Arg-Gly-Asp peptidomimetic vitronectin receptor antagonist SB 265123 for prevention of bone loss in osteoporosis.

Lark MW, Stroup GB, Hwang SM, James IE, Rieman DJ, Drake FH, Bradbeer JN, Mathur A, Erhard KF, Newlander KA, Ross ST, Salyers KL, Smith BR, Miller WH, Huffman WF, Gowen M.

J Pharmacol Exp Ther. 1999 Nov;291(2):612-7.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk